Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Wieslaw B. Furmaga

Wieslaw B. Furmaga

Associate prof
Graduate School of Biomedical Sciences
USA

Biography

Dr.Wieslaw B. Furmaga, is currently working as Interim Medical Director at Point of Care Department, University Hospital, San Antonio, TX, He has done his MD in Medicine from Collegium Medicum, at The Jagiellonian University Krakow, Poland, Internship in Pediatrics Surgery, OBGYN and Medicine from Clinical Hospitals Krakow, Rzeszow, Poland, Residency in Residency -Surgery, Internal Medicine/Pediatrics from Clinical Hospitals Krakow, Rzeszow & Lublin, Poland, Residency PG-1 and PG-2; AP/CP Pathology, Residency Program from University of Medicine & Dentistry of New Jersey Newark , NJ, Residency PG-3 and PG-4; AP/CP Pathology Residency Program Hartford Hospital Hartford , CT, Clinical Fellowship in Clinical Chemistry and Toxicology from Hartford Hospital Hartford , CT, MMS Clinical Investigation UT Health Science Center at San Antonio San Antonio , TX

Research Interest

Clinical Investigation - I graduated from the Masters Degree in Clinical Investigation program in 2013. I have reviewed several publications related to the diagnostic marker discovery. In addition, I have been invited to write a chapter entitled: diagnostic markers for hemorrhagic shock (date for submission: November 1st 2015, for "Advances in Clinical Chemistry"; Elsevier). Proteomics - The goal of proteomics research is to detect and measure the concentration of all proteins present in body fluids or in tissue during the pathological process. The composition of all proteins and their concentration may be a distinguishing characteristic of disease, and it may be used as a diagnostic marker. For biomarker discovery, a proteomics approach differs significantly from traditional single target methodology. In the proteomics approach, an entire collection of protein is identified and characterized as the test group of a particular disease and is subsequently compared to the protein collection from the control group. The differing protein is identified and subsequently tested during the confirmatory investigation in a clinical setting. The scale of experimentation and amount of data produced by proteomics is enormous, which requires a more systematic approach than conventional methodology. As an expert in proteomics, I have written two book chapters and a new revised chapter will be sent to publisher on July 31,2015.